TABLE 4.
Association of promoter hypermethylation status of candidate genes with patient’s clinico-pathological features in EOC tissue samples. p-value: Pearson’s chi-square and Fisher’s exact tests. Abbreviation: Pos: biomarker panel positive for methylation; Neg: biomarker panel negative for methylation; NS: not significant. A positive biomarker panel is defined as when either or both gene promoter show methylation.
Tissue | No. of patients | HOXA9 a | HIC1 a | SOX1 | RASSF1A | SFRP1 | SPARC | DAPK1 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Feature | M | U | M | U | M | U | M | U | M | U | M | U | M | U | |
Tumor | 85 | 70 | 15 | 68 | 17 | 67 | 18 | 61 | 24 | 63 | 22 | 52 | 33 | 59 | 26 |
Healthy | 35 | 5 | 30 | 8 | 27 | 7 | 28 | 10 | 25 | 10 | 25 | 11 | 24 | 10 | 25 |
P value | <0.0001*** | <0.0001*** | < 0.0001*** | < 0.0001*** | < 0.0001*** | 0.0046** | <0.0001*** | ||||||||
Histology | |||||||||||||||
Serous | 74 | 61 | 13 | 58 | 16 | 58 | 16 | 53 | 21 | 53 | 21 | 47 | 27 | 51 | 23 |
Mucinous | 6 | 5 | 1 | 6 | 0 | 5 | 1 | 5 | 1 | 6 | 0 | 5 | 1 | 4 | 2 |
Benign | 5 | 4 | 1 | 4 | 1 | 4 | 1 | 3 | 2 | 4 | 1 | 0 | 5 | 4 | 1 |
P value | NS | NS | NS | NS | NS | 0.0096** | NS | ||||||||
FIGO stage | |||||||||||||||
I/II | 20 | 16 | 4 | 14 | 6 | 14 | 6 | 14 | 6 | 14 | 6 | 11 | 9 | 14 | 6 |
III/IV | 65 | 54 | 11 | 54 | 11 | 53 | 12 | 47 | 18 | 49 | 16 | 41 | 24 | 45 | 20 |
P value | NS | NS | NS | NS | NS | NS | NS | ||||||||
Age (Median =50) | |||||||||||||||
≥ Median age | 64 | 31 | 33 | 33 | 31 | 34 | 30 | 33 | 31 | 34 | 30 | 32 | 32 | 34 | 30 |
< Median age | 56 | 44 | 12 | 43 | 13 | 41 | 15 | 38 | 18 | 39 | 17 | 31 | 25 | 35 | 21 |
P value | 0.0007*** | 0.0047** | 0.0253* | NS | NS | NS | NS | ||||||||
Menopausal status | |||||||||||||||
Pre | 53 | 41 | 12 | 40 | 13 | 40 | 13 | 36 | 17 | 38 | 15 | 29 | 24 | 35 | 18 |
Post | 67 | 34 | 33 | 36 | 31 | 35 | 32 | 35 | 32 | 35 | 32 | 34 | 33 | 34 | 33 |
P value | 0.0042** | 0.0216* | 0.0132* | NS | 0.0385* | NS | NS |
Tissue | No. of patients | HOXA9 + HIC1 a | HOXA9 + SOX1 | HIC1+ SOX1 | HOXA9+ RASSF1A | HIC1+ SFRP1 | DAPK1+ SOX1 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Feature | Pos | Neg | Pos | Neg | Pos | Neg | Pos | Neg | Pos | Neg | Pos | Neg | |
Tumor | 85 | 75 | 10 | 73 | 12 | 71 | 14 | 65 | 20 | 67 | 18 | 62 | 23 |
Healthy | 35 | 4 | 31 | 4 | 31 | 4 | 31 | 7 | 28 | 8 | 27 | 8 | 27 |
P value | <0.00001*** | < 0.0001*** | < 0.0001*** | < 0.0001*** | < 0.0001*** | < 0.0001*** | |||||||
Histology | |||||||||||||
Serous | 74 | 65 | 9 | 61 | 13 | 60 | 14 | 57 | 17 | 57 | 17 | 53 | 21 |
Mucinous | 6 | 6 | 0 | 5 | 1 | 6 | 0 | 5 | 1 | 6 | 0 | 4 | 2 |
Benign | 5 | 4 | 1 | 4 | 1 | 4 | 1 | 2 | 3 | 4 | 1 | 4 | 1 |
P value | NS | NS | NS | NS | NS | NS | |||||||
FIGO stage | |||||||||||||
I/II | 20 | 16 | 4 | 15 | 5 | 14 | 6 | 13 | 7 | 14 | 6 | 14 | 6 |
III/IV | 65 | 59 | 6 | 55 | 10 | 56 | 9 | 51 | 14 | 53 | 12 | 47 | 18 |
P value | NS | NS | NS | NS | NS | NS | |||||||
Age (Median =50) | |||||||||||||
≥ Median age | 64 | 33 | 31 | 31 | 33 | 31 | 33 | 31 | 33 | 32 | 32 | 30 | 34 |
< Median age | 56 | 48 | 8 | 43 | 13 | 43 | 13 | 39 | 17 | 43 | 13 | 37 | 19 |
P value | <0.0001*** | 0.0024** | 0.0024** | 0.0258* | 0.0027** | 0.0432* | |||||||
Menopausal status | |||||||||||||
Pre | 53 | 45 | 8 | 40 | 13 | 41 | 12 | 37 | 16 | 40 | 13 | 37 | 16 |
Post | 67 | 36 | 31 | 34 | 33 | 33 | 34 | 33 | 34 | 35 | 32 | 30 | 37 |
P value | 0.0004*** | 0.0079** | 0.0023** | 0.0265* | 0.0132* | 0.0093** |
Promoter hypermethylation of DNA methylation markers-HOXA9 and HIC1 in singleplex and multiplex MethyLight assay analyzed in tissue samples has been previously published (Singh et al., 2020).